Cas:877877-35-5 TW-37 manufacturer & supplier

Chemical Name:TW-37

CAS.NO:877877-35-5

Synonyms:N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide;Benzamide, N-[4-[[2-(1,1-dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]-;2,3,4-Trihydroxy-5-(2-isopropylbenzyl)-N-(4-{[2-(2-methyl-2-propanyl)phenyl]sulfonyl}phenyl)benzamide;N-{4-[(2-tert-butylphenyl)sulfonyl]phenyl}-2,3,4-trihydroxy-5-[2-(propan-2-yl)benzyl]benzamide;N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]benzamide;TW-37

Molecular Formula:C₃₃H₃₅NO₆S

Molecular Weight:573.699

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:723.7±60.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.631

PSA:132.31000

Exact Mass:573.218506

LogP:8.74

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,TW-37 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzamide, N-[4-[[2-(1,1-dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]- Use and application,N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide technical grade,usp/ep/jp grade.

Related News: In 2016, in order to promote the innovative development, transformation and upgrading of the pharmaceutical industry, the Development and Reform Commission led the compilation of the Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry, which put forward requirements for all aspects of the medical industry and specifically proposed support for the field of chemical raw materials. . TW-37 manufacturer Though Innova previously applied for a regulatory green light, the test has not been authorized or approved by the FDA for use in the U.S.—however, during inspections of the company’s California facilities in March and April, FDA investigators said they found the test was already being sold and distributed. TW-37 supplier In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. TW-37 vendor The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. TW-37 factory What’s the background?